Zhaoke Ophthalmology Pharmaceutical Ltd.
http://www.zhaokepharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zhaoke Ophthalmology Pharmaceutical Ltd.
Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Asia Deal Watch: Zhaoke, PanOptica Finalize Neovascular Eye Disease Alliance
Plus deals involving Zai Lab/MacroGenics, Ono/Rafael Pharmaceuticals, Beijing Podconley/Norgine, Nuance/Verona and BeiGene/Shoreline.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
- China Ophthalmology Focus Limited (COPFL)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice